Table 6. Clinical characteristics of patients with or without seroconversion to one of the amoeba-associated bacteriaa.
| Clinical characteristics | Seroconversion (N=12) | No seroconversion (N=18) | p value |
|---|---|---|---|
| Demographic data | |||
| Median age in y (IQR) | 35 (25–43) | 24 (21–52) | 0.85 |
| Male (%) | 10 (83.3) | 15 (83.3) | 1 |
| Risk and potential confounding factors | |||
| Underlying disease (%) | 2 (16.6) | 3 (16.6) | 1 |
| Circulation injury (%) | 9 (75) | 14 (77.8) | 1 |
| Median APACHE IIa score (IQR) | 21 (14–4) | 23 (16–34) | 0.12 |
| Intubation in ICU (%) | 8 (66.6) | 7 (38.9) | 0.26 |
| Median hospitalization days (IQR) | 25 (19–41) | 17 (10–23) | 0.094 |
| Median intubation duration in days (IQR) | 11 (7–20) | 11 (7–20) | 0.8 |
| Median number of serum samples (IQR) | 3 (3–5) | 3 (2–4) | 0.12 |
| Clinical data | |||
| VAP (%) | 10 (83.3) | 7 (38.9) | 0.026 |
| Unexplained VAP (%) | 6 (50) | 2 (11.1) | 0.034 |
| Fever > 38.5 °C (%) | 12 (100) | 17 (84.4) | 1 |
| Unexplained fever (%) | 7 (58.3) | 11 (39.3) | 0.27 |
| SIRS (%) | 12 (100) | 11 (61.1) | 0.024 |
| Unexplained SIRS (%) | 7 (58.3) | 3 (14.3) | 0.045 |
| Death (%) | 2 (16.7) | 8 (44.4) | 0.23 |
| Paraclinical data | |||
| Leukocytes > 12 g/L (%) | 12 (100) | 14 (77.8) | 0.13 |
| Platelets > 500 g/L (%) | 5 (41.7) | 6 (33.3) | 0.7 |
| PCR detection of ARB in BAL samples(%) | 2 (17) | 0 | 0.15 |
aIQR, interquartile range; VAP, ventilator-associated pneumonia; SIRS, Systemic Inflammatory Response Syndrome; APACHE II, Acute Physiology and Chronic Health Evaluation II; PCR, polymerase chain reaction; ARB, angiotensin receptor blockers; BAL, bronchoalveolar lavage samples; bold p values are those that are significant (<0.05).